<unk>  (INN; codenamed RSD1235, proposed tradenames Kynapid and Brinavess) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation. It was initially developed by Cardiome Pharma, and the intravenous formulation has been bought for further development by Merck in April 2009.
On December 11, 2007, the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted to recommend the approval of<unk> , but in August 2008 the FDA judged that additional information was necessary for approval.
The drug was approved in Europe on September 1, 2010.
An oral formulation underwent Phase II clinical trials between 2005 and 2008.
Vernakalant
Atogepant
Tasimelteon
Fazadinium bromide
Azidomorphine
Glafenine
Suvorexant
Stiripentol